xosawewaqa.wordpress.com
Genzyme (NASDAQ: GENZ) found a viruzs strain and stopped production of two drugs atthe Mass., facility. The strain, Vesivirus 2117, apparentluy does not cause human infectiom but interrupts the growth of cells that are used to make Aldurazyme — a treatment for MPS I, a rare and fatal diseass caused by an enzyme deficiency was last filled at the Genzymer facility in September 2008, accordingy to BioMarin (NASDAQ: BMRN). The company has about 10 months of viale inventoryon hand, it and uses a second fill finisbh supplier. A third supplier is expectedd to be qualified laterthis year, BioMarin BioMarin makes the bulk material used in Aldurazymw at its Novato facility.
The Food and Drug Administrationh hadinspected Genzyme’s plant in Septembe r and October and reportedly was concerned about controls to protect against
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment